Advertisement
Research ArticleArticle

Atypical Neuroleptics Enhance Histamine Turnover in Brain Via 5-Hydroxytryptamine2A Receptor Blockade

S. Morisset, U. G. Sahm, E. Traiffort, J. Tardivel-Lacombe, J. M. Arrang and J.-C. Schwartz
Journal of Pharmacology and Experimental Therapeutics February 1999, 288 (2) 590-596;

Abstract

Clozapine and olanzapine behave as weak H3-receptor antagonists in vitro with Ki values around 1 and 50 μM, respectively. Despite these modest apparent affinities, both compounds given orally to mice, nearly doubled steady-statetele-methylhistamine levels in brain, with ED50 values as low as 1 and 3 mg/kg, respectively, an effect comparable to those of potent H3-receptor antagonists. This effect corresponded to an enhancement of histamine turnover rate from 45 to 73 ng/g/h as measured in the case of olanzapine using the pargyline test. Other antipsychotics displaying, such as clozapine and olanzapine, high 5-hydroxytryptamine (5-HT)2A receptor antagonist potency, i.e., risperidone, thioridazine, seroquel, and iloperidone, also enhanced markedlytele-methylhistamine levels. This effect was 1) additive with that of a pure H3-receptor antagonist, ciproxifan, 2) mimicked by a 5-HT2A receptor antagonist, ketanserin, 3) reversed by a 5-HT2A receptor agonist, DOI, 4) not shared by antipsychotics with low affinity for the 5-HT2Areceptor, i.e., haloperidol, sulpiride, raclopride, or remoxipride that, on the contrary, tended to reducetele-methylhistamine levels. We conclude that in contrast to “typical” antipsychotics, “atypical” antipsychotics stimulate histamine neuron activity via blockade of the 5-HT2A receptor in vivo. This effect does not appear to account for their reduced extrapyramidal side-effects but may underlie their pro-cognitive properties.

During the last decade a number of novel antipsychotic drugs were developed with the aim of obtaining agents displaying therapeutic advantages over the first drug generation, often designated “typical” antipsychotic drugs. These include a lower propensity to elicit extrapyramidal side-effects, an improved therapeutic efficacy on negative and affective symptomatology of schizophrenia as well as on refractory forms of the disease. These drugs, often designated “atypical” antipsychotics, a rather vague terminology, were mostly modeled after clozapine, which seems to display such advantages but is not devoid of toxic side-effects (for reviews see Meltzer and Nash, 1991;Buchanan, 1995; Kinon and Lieberman, 1996). In addition to dopamine receptors blocked by all antipsychotics, clozapine potently blocks with Ki of 1 to 20 nM a variety of aminergic receptors including muscarinic, α1adrenergic, H1 histaminergic, and 5-hydroxytryptamine (5-HT)2, 5-HT6, and 5-HT7serotoninergic receptors. Although there are many individual differences among drugs designated “atypical antipsychotics”, all these compounds share some properties of clozapine, e.g., they display significant affinity toward several aminergic receptors and/or lower propensity to cause catalepsy in rodents as well as positive effects on animal models of cognition (reviewed by Arnt and Skarsfelt, 1998). To date the results of clinical studies have confirmed the predictions of lower incidence of extrapyramidal side-effects after administration of these novel antipsychotic drugs at doses that demonstrate antipsychotic efficacy. Controlled studies with some of these drugs, e.g., clozapine, risperidone, or olanzapine, have shown them to decrease negative symptomatology, whereas haloperidol is ineffective. It is not entirely clear to which receptor subtype(s) blockade, clozapine and these novel antipsychotic agents owe their peculiar animal behavioral and human clinical properties. Recently clozapine was shown to block the histamine H3 receptor as evidenced on the release of noradrenaline or serotonin from brain slices and confirmed in radioligand binding assays, whereas typical antipsychotics were ineffective in this respect (Kathmann et al., 1994; Alves-Rodrigues et al., 1995).

In fact, the H3 receptor was initially described as an inhibitory autoreceptor through which histamine controls its own synthesis in and release from tuberomammillary neurons in brain (Arrang et al., 1987), so that it could be predicted that its blockade by a drug like clozapine should enhance the activity of these neurons in vivo.

The role, if any, of histaminergic neurons in psychiatric diseases is not well understood (Schwartz et al., 1995) but a relationship between histamine and schizophrenia is suggested by several pieces of evidence. In agreement, decreased H1 receptor-mediated response to histamine is consistently observed among schizophrenic patients (Rauscher et al., 1980; Nakai et al., 1991). Levels oftele-methylhistamine (t-MeHA), the major histamine metabolite in brain (Schwartz et al., 1971, 1991) are significantly enhanced in the cerebrospinal fluid of schizophrenic patients (Prell et al., 1995). Finally, a polymorphism within the H2 receptor gene was recently reported to be associated with schizophrenia (Orange et al., 1996).

We have evaluated the changes in histamine neuron activity induced in mice by administration of a variety of antipsychotic drugs by measuring the levels of t-MeHA in several brain regions.

Materials and Methods

[125I]Iodoproxyfan Binding Assay.

The procedure was that described by Ligneau et al. (1994). Aliquots of membrane suspension from mouse cerebral cortex, striatum, or hypothalamus (20 μg of protein) were incubated for 60 min at 25°C in 50 mM Na2HPO4/KH2PO4buffer, pH 6.8 with [125I]iodoproxyfan alone or together with competing drugs. Specific binding was defined as that inhibited by 1 μM (R)α-MeHA. Incubations were performed in triplicate and stopped by dilution with ice-cold medium, followed by rapid filtration through glass microfiber filters (GF/B Whatman, Clifton, NJ) presoaked in 0.3% polyethyleneimine. Radioactivity trapped on the filters was measured with a LKB (Rockville, MD) gamma counter (82% efficiency).

[3H]HA Release from Synaptosomes.

Release experiments with synaptosomes were performed according to Arrang et al. (1985) with slight modifications (Garbarg et al., 1992). A crude synaptosomal preparation from mouse cerebral cortex was preincubated for 30 min with [3H]l-histidine (0.4 μM) at 37°C. Synaptosomes were then washed and resuspended in fresh 2 mM K+-Krebs-Ringer’s medium. After a 5-min preincubation in the presence of drugs, synaptosomes were incubated for 2 min with 2 or 30 mM K+. When required, R(α)-MeHA (1 μM), a specific H3 receptor agonist (Arrang et al., 1987) was added to the medium. Incubations were ended by a rapid centrifugation and [3H]HA levels in the supernatant were determined (Garbarg et al., 1983).

t-MeHA Levels in Brain

Male Swiss mice (18–20 g) (Iffa-Credo, L’Arbresle, France) were fasted for 12 h before drug administration. Administrations were performed with drugs dissolved in 1% lactic acid and diluted as required in 1% methylcellulose or 0.9% NaCl for p.o. and i.p. administration, respectively. Rectal temperature of the animals was measured and, when necessary, maintained at 37°C by using a heating lamp. Animals were sacrificed by decapitation. The brain was dissected out and the cerebral cortex, striatum, and hypothalamus were homogenized in 10 volumes (w/v) of ice-cold perchloric acid (0.4 M). The perchloric acid extracts were centrifuged (4000g for 20 min) and the supernatant was stored at −20°C. t-MeHA levels were determined by radioimmunoassay after derivatization of samples with benzoquinone as described previously (Garbarg et al., 1989b, 1992).

Assessment of Catalepsy.

For assessment of catalepsy in an all-or-none manner, mice received haloperidol (0.25 mg/kg, i.p.) and, 1 h later, each mouse was placed gently so that both front limbs rested on top of a horizontal rod placed at a height of 5 cm above the floor. When required, H3-receptor ligands were given 1 h before haloperidol. An animal was considered to be in catalepsy if it remained with its hind legs on the floor and its front limbs on the rod for more than 5 s.

For assessment of catalepsy duration, mice received haloperidol (0.8 mg/kg, i.p.) and, 1 h later, were placed in the position described before. When required, H3-receptor ligands were administered 1 h before haloperidol. Scoring consisted in measuring the time during which they kept the position. Scoring were made under unblinded conditions.

Analysis of Data.

Maximal effects, ED50, IC50, and pseudo Hill coefficients (nH) were determined by nonlinear regression using an iterative computer least-squares method and a one-site cooperative model (Parker and Waud, 1971). Ki values of drugs at the H3 receptor were calculated from their IC50values, assuming a competitive antagonism and using the relationshipKi = IC50/(1 +S/Kd) where S andKd represent, respectively, either the concentration and the apparent dissociation constant of [125I]iodoproxyfan in binding experiments or the concentration and EC50 of histamine in release experiments (Cheng and Prusoff, 1973). Protein contents were determined according to the method of Lowry et al. (1951), using bovine serum albumin as the standard. Statistical evaluation of the results was by Student’st test.

Radiochemicals and Drugs.

The drugs and their sources were as follows: ciproxifan [cyclopropyl-(4-(3–1H-imidazol-4-yl)propyloxy)phenyl)ketone], nafadotride and (R)α-MeHA (Laboratoire Bioprojet, Paris, France), risperidone and iloperidone (Hoechst-Roussel Pharmaceuticals, Somerville, NJ), clozapine and thioridazine (Sandoz, Basel, Switzerland), olanzapine (Eli Lilly and Co., Indianapolis, IN), seroquel (Zeneca, Wilmington, DE), haloperidol (Janssen Pharmaceutica, Beerse, Belgium), raclopride and remoxipride (Astra, Läkemedel AB, Sweden), ketanserin and (±)-DOI [(±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride] (Research Biochemicals International, Natick, MA), (−)sulpiride (Synthélabo, Paris, France). [125I]iodoproxyfan (2000 Ci/mmol) and l-[2,5-3H]histidine (50 Ci/mmol) were purchased from Amersham (Amersham, UK). All drug weights are expressed as free base.

Results

Interaction of Clozapine and Olanzapine with the Histamine H3 Receptor.

The specific binding of [125I]iodoproxyfan, a selective H3 receptor radioligand (Ligneau et al., 1994), to membranes from mouse cerebral cortex, striatum, and hypothalamus was monophasically inhibited by clozapine and olanzapine in increasing concentrations with pseudo Hill coefficients (nH) of 0.9 ± 0.1 and 0.9 ± 0.2, respectively (Fig. 1 and data not shown). Analysis of the displacement curve of the binding obtained in the three brain regions studied yielded IC50 values of 2 to 5 μM for clozapine and 30 to 100 μM for olanzapine (Fig. 1 and data not shown). Taking into account a Kd value of 72 ± 9 pM for [125I]iodoproxyfan, as determined from saturation kinetics at equilibrium in the three regions (data not shown), a calculated Kivalue of 1 to 3 μM was found for clozapine and of 20 to 70 μM for olanzapine (Table 1).

Figure 1
Figure 1

Inhibition by clozapine and olanzapine of [125I]iodoproxyfan binding to membranes from mouse striatum. Membranes were incubated for 1 h at 25°C with [125I]iodoproxyfan (30 pM) and drugs in increasing concentrations. Specific binding was defined as that displaced by 1 μM (R)α-MeHA, corresponded to 71% of total and represented 72 ± 3 fmol/mg protein. Results are expressed as percentage of this value. Each point represents the mean of results from two to three different experiments with triplicate determinations.

View this table:
Table 1

Potencies of clozapine and olanzapine as inhibitors of [125I]Iodoproxyfan binding in various mouse brain regions

Clozapine was examined for its ability to modulate HA release from cortical synaptosomes labeled withl-[3H]histidine (Arrang et al., 1985). It failed to mimic the autoinhibitory effect of 1 μM exogenous HA but progressively and completely reversed it at the presynaptic H3 receptor with an IC50value of 10 ± 3 μM (Fig. 2). Taking into account an EC50 value of 0.06 μM for exogenous HA (Garbarg et al., 1992), an apparentKi value of 0.6 μM was calculated for clozapine acting as an H3-receptor antagonist in this functional model.

Figure 2
Figure 2

Effect of clozapine on the inhibition by exogenous HA of the K+-induced [3H]HA release from synatosomes of mouse cerebral cortex. Synaptosomes preincubated with l-[3H]histidine were incubated for 5 min in the presence of HA (1 μM) and clozapine in increasing concentrations, and subsequently depolarized for 2 min in the presence of 30 mM K+ (final concentration). In the absence of added agents, [3H]HA release induced by 30 mM K+(expressed as percent of total [3H]HA over spontaneous efflux) represented 19 ± 3%. Results are expressed as percentage of this value. Each point represents the results from three independent experiments with triplicate determinations.

Effects of Typical and Atypical Antipsychotic Drugs ont-MeHA Levels.

The effects of 10 antipsychotic drugs belonging to various chemical classes and classified as either typical or atypical agents were analyzed on t-MeHA level, an index of HA neuronal activity in three mouse brain regions. In cerebral cortex, striatum, and hypothalamus, acute administration of haloperidol, sulpiride, raclopride, or remoxipride tended to slightly decrease (by ∼10–30%) basal t-MeHA levels, but this inhibitory effect was hardly significant except in striatum (Fig.3). In contrast, all other agents, sometimes classified as atypical antipsychotics, strongly and significantly enhanced t-MeHA level in the cerebral cortex, striatum, and hypothalamus. In the first two regions, the increase was of similar amplitude (about +80%) with all these compounds and in the same range as that observed after oral administration of the potent and selective HA H3-receptor antagonist ciproxifan (about +100%) (Ligneau et al., 1998), whereas it was of a lower amplitude (about +40%) in the hypothalamus (Fig. 3; Table 2). Clozapine, as well as olanzapine, displayed a similar potency at increasingt-MeHA levels in the three brain regions, with ED50 values of ∼1 and ∼3 mg/kg, respectively (Fig.4 and Table 2). In the striatum,t-MeHA accumulation induced by oral administration of olanzapine was clearly additive with that induced by pargyline, a monoamine oxidase inhibitor and previously shown to be an index of neuronal HA turnover (Schwartz et al., 1991). In mice receiving pargyline, t-MeHA level increased linearly with time at a rate of 45 ng/g/h, which was enhanced to 73 ng/g/h in mice receiving pargyline and olanzapine (Fig. 5).

Figure 3
Figure 3

Effects of typical and atypical antipsychotics ont-MeHA levels in three brain regions. Mice were sacrificed 3 h after the oral administration of vehicle, haloperidol (1 mg/kg), ciproxifan (3 mg/kg), raclopride, remoxipride, risperidone (5 mg/kg), iloperidone (20 mg/kg), thioridazine, seroquel, clozapine, olanzapine (30 mg/kg), or sulpiride (100 mg/kg). Results from at least 15 mice are expressed as percent change as compared with control t-MeHA levels (59 ± 2, 112 ± 4, and 272 ± 6 ng/g in the cerebral cortex, striatum and hypothalamus respectively). *P < .05, **P< .01, ***P < .001 as compared with controls.

View this table:
Table 2

Effects of clozapine and olanzapine on t-MeHA levels in various mouse brain regions

Figure 4
Figure 4

Changes in t-MeHA levels in mice receiving clozapine (○) or olanzapine (•) in increasing dosages. Mice were sacrificed 3 h after oral administration of the drug. Values are means ± S.E.M. from 12 to 20 animals.

Figure 5
Figure 5

Time course of the changes in striatalt-MeHA levels in mice treated with pargyline and/or olanzapine. Mice were sacrificed at various times after the administration of olanzapine (30 mg/kg, p.o.) and/or pargyline (65 mg/kg, i.p.). Values are means ± S.E.M. from 12 to 18 animals. *P < .01, **P < .001 as compared with controls; §P < .01 as compared with pargyline alone.

Effects of Clozapine, Olanzapine, 5-HT2A Receptor Ligands, and Haloperidol on t-MeHA Levels in the Absence or Presence of a H3-Receptor Antagonist.

Oral administration of ciproxifan alone in a maximally effective dosage (3 mg/kg) (Ligneau et al., 1998) induced a doubling of t-MeHA levels in the cerebral cortex, striatum, and hypothalamus (Figs. 3 and6). This effect of the H3-receptor antagonist was further enhanced by coadministration of clozapine, olanzapine, or ketanserin, a preferential 5-HT2A-receptor antagonist (Fig. 6). A significant increase in t-MeHA level was also observed 3 h after the administration of ketanserin alone (8 mg/kg, p.o.), as compared with control mice, in the cerebral cortex and striatum (+54 and +81%, respectively, Fig. 6) as well as hypothalamus (+42%, data not shown). The coadministration of ketanserin did not further enhance the effect of clozapine in the cerebral cortex and striatum (Fig.7). DOI, a preferential 5-HT2A/2C-receptor agonist, did not change significantly t-MeHA level when used alone but strongly decreased the t-MeHA accumulation induced by clozapine (−62 and −72% in the cerebral cortex and striatum, respectively) (Fig. 7). Given at a dose of 5 mg/kg DOI reversed the effect of clozapine by 58% (not shown). Prazosin (5 mg/kg, p.o.) an α1-receptor antagonist did not modify t-MeHA levels.

Figure 6
Figure 6

The increase in t-MeHA level induced by clozapine (CLZ, 30 mg/kg), olanzapine (OLZ, 30 mg/kg), or ketanserin (KET, 8 mg/kg) is additive with that induced by ciproxifan (CPX, 3 mg/kg), a H3-receptor antagonist. Mice were sacrificed 3 h after oral administration of vehicle or drug. Values are means ± S.E.M. from 12 to 18 animals. *P < .01, **P < .001 as compared with controls; §P < .05, §§P < .01, as compared with ciproxifan alone.

Figure 7
Figure 7

Effect of ketanserin and DOI, a preferential 5-HT2A-receptor antagonist and agonist, respectively on thet-MeHA accumulation induced by clozapine. Clozapine was given orally at a dose of 30 or 6 mg/kg when coadministered with ketanserin (KET, 8 mg/kg, p.o.) or DOI (20 mg/kg, s.c.), respectively. Values are means ± S.E.M. of data from 8 to 12 animals. *P < .01 as compared with controls; §P < .05 as compared with clozapine alone.

Although it induced a slight and nonsignificant decrease int-MeHA level (Figs. 3 and 8), haloperidol, a D2-like receptor antagonist, significantly inhibited by ∼50% the t-MeHA accumulation induced by ciproxifan in the cerebral cortex, striatum (Fig. 8), and hypothalamus (not shown). This decreasing effect of haloperidol was not observed on the t-MeHA accumulation induced by coadministration of ketanserin (Fig. 8).

Figure 8
Figure 8

Effect of haloperidol (HALO, 1 mg/kg, p.o.), ont-MeHA accumulation induced by ciproxifan (3 mg/kg, p.o.) or by ketanserin (8 mg/kg,p.o.). Mice were sacrificed 3 h after the administration of haloperidol alone or in combination with ciproxifan or ketanserin. Values are means ± S.E.M. of data from 10 to 16 animals. *P < .01; **P < .001 as compared with controls; §P < .05, §§P < .01 as compared with ciproxifan alone.

Effect of (R)α-MeHA and Ciproxifan on Catalepsy in Mice.

(R)α-MeHA or ciproxifan, tested in a maximally effective dosage (20 and 3 mg/kg, respectively) (Garbarg et al., 1989a;Ligneau et al., 1998), neither produced any significant catalepsy when administered alone nor modified haloperidol-induced catalepsy in mice (Table 3).

View this table:
Table 3

Effects of a histamine H3-receptor agonist or antagonist on haloperidol-induced catalepsy

Discussion

Our main finding is that clozapine, as well as a number of other atypical antipsychotic drugs, activate cerebral histaminergic neurons, as judged from the enhanced level of t-MeHA they induce in several brain areas.

This was not unexpected in the case of clozapine, a drug previously shown to be unique among antipsychotics in that it displays significant antagonist activity at the H3-heteroreceptor controlling [3H]noradrenaline release in brain slices as well as in radioligand binding tests (Kathmann et al., 1994;Alves-Rodrigues et al., 1995). In this study, we have confirmed this activity, showing that the drug reverses the action of histamine at the H3-autoreceptor, controlling [3H]HA release from synaptosomes (Arrang et al., 1985; Garbarg et al., 1992) and inhibits [125I]iodoproxyfan binding to cerebral membranes (Ligneau et al., 1994). The apparentKi value (about 1 μM) of clozapine at H3 receptors regulating HA release is in the same range as that reported at H3 receptors regulating noradrenaline (Kathmann et al., 1994) or serotonin (Alves-Rodrigues et al., 1995) release. These similarKi values at H3receptors of a nonimidazole compound further argue against the existence of several H3 receptor subtypes previously suggested by functional studies (Clapham and Kilpatrick, 1992; Leurs et al., 1996; Schlicker et al., 1996). The clozapine-related atypical antipsychotic drug olanzapine also inhibited [125I]iodoproxyfan binding at the H3 receptor but with a very modest potency, its apparent Ki value being of about 50 μM.

Many previous studies, using thioperamide and a variety of other antagonists, have shown that H3-receptor blockade in vivo activates histaminergic neuron activity (Schwartz et al., 1991,1995) and enhances [3H]histamine synthesis (Arrang et al., 1987), endogenous HA release (Itoh et al., 1991;Mochizuki et al., 1991), and levels of t-MeHA, a major metabolite in brain (Garbarg et al., 1989a,b; Oishi et al., 1989). These effects all reflect the tonic inhibition of histaminergic neurons that endogenous HA exerts via H3-autoreceptors and no other tonic inhibitory mechanism controlling the activity of these neurons has been reported. In addition, clozapine administration resulted in an enhancement of t-MeHA levels of about 100%, i.e., in the same range as that elicited by H3-receptor antagonists such as thioperamide (Garbarg et al., 1989a) or ciproxifan (Ligneau et al., 1998 and present data). Also, as in the case of H3-receptor antagonists (Schwartz et al., 1991), the effect of clozapine on steady-state t-MeHA levels resulted from an enhanced HA turnover rate, shown to be nearly doubled according to its evaluation via measurement of pargyline-inducedt-MeHA accumulation (see Results).

Nevertheless, despite these various observations, several findings led us to the conclusion that this effect could not be ascribed to blockade of H3 receptors. First, in vitro, clozapine was 100 to 1000 times less potent at the H3-receptor than thioperamide, both in binding and release experiments. However, its in vivo effect surprisingly occurred with an ED50 value in the same milligram per kilogram range (Fig. 4; Table 2) as that previously reported for thioperamide in the same test (Garbarg et al., 1989a). Even more strikingly, an effect of similar amplitude and occurring with a similarly low ED50 value (∼3 mg/kg) was obtained for olanzapine which displays a 50-fold lower potency than clozapine at the H3 receptor in vitro and the same increase in t-MeHA levels could be observed with various other atypical antipsychotics that display low, if any, affinity at this receptor (Schlicker and Marr, 1996). Second, the effects of clozapine and olanzapine ont-MeHA levels were additive with those of ciproxifan used in a maximally effective dose. Moreover, despite its higher affinity at the H3-receptor, clozapine at the highest dose tested (100 mg/kg) did not further enhance t-MeHA level, strongly suggesting a low degree of H3-receptor occupation.

If it was not mediated by the H3 receptor, what could be the mechanisms through which clozapine and other atypical antipsychotics activate histaminergic neurons?

A characteristic property shared by all these antipsychotic compounds is their relatively low affinity for the D2receptor and high affinity for the 5-HT2A/2Creceptor, leading to a higher 5-HT2A/D2 affinity ratio as compared with typical neuroleptics (Meltzer and Nash, 1991). Accordingly, these compounds elicit a predominant 5-HT2A receptor occupancy in vivo accompanied by a moderate D2-receptor occupancy, a balance proposed to underlie their atypical profile (Brunello et al., 1995;Schotte et al., 1996; Busatto and Kerwin, 1997). It was therefore of interest to assess the effect of 5-HT2A-receptor ligands on HA neuron activity. Ketanserin, a preferential 5-HT2A receptor antagonist, mimicked the enhancing effect of atypical antipsychotics on t-MeHA levels in mouse cerebral cortex, striatum, and hypothalamus and, like that of the latters, its effect was additive with that induced by ciproxifan (Fig. 6). DOI, a 5-HT2A/2C-receptor agonist, did not modify t-MeHA level but strongly reversed the effect of clozapine. Our findings therefore show that endogenous serotonin tonically inhibits HA neurons via 5-HT2Areceptors, an effect blocked by clozapine. These 5-HT2A receptors could be located on HA neurons themselves, on interneurons or nearby axon terminals impinging on the formers. This inhibitory effect of serotonin was apparently never described before but the 5-HT2A receptor displays inhibitory effects on the spontaneous activity of locus ceruleus noradrenergic neurons (Rasmussen and Aghajanian, 1988). In agreement with the blockade of 5-HT2A receptors by atypical neuroleptics, the effect of clozapine was not additive with that of ketanserin and blockade of α1 adrenergic receptors, previously proposed also to contribute to the atypical profile of clozapine (Baldessarini et al. 1992), did not modifyt-MeHA levels. This strongly suggests that the activation of histaminergic neurons by clozapine (and other novel antipsychotics) is entirely attributable to 5-HT2A receptor blockade and that, even at the highest clozapine dosage, H3-receptor blockade does not contribute.

Interestingly, antipsychotics devoid of significant affinity for the 5-HT2A receptor, such as haloperidol or the benzamide derivatives, not only failed to enhance t-MeHA levels but, on the contrary, tended to decrease it. This inhibitory effect was particularly clear in striatum (Fig. 3) or, in other regions, when t-MeHA levels had been enhanced by treatment with ciproxifan (Fig. 8 and data not shown). It is consistent with the findings that endogenous dopamine released by administration of amphetamine enhances striatal HA release by interacting with D2-like receptors (Ito et al., 1996). It is interesting to underline that the tendency of antipsychotic drugs to inhibit HA neuron activity via blockade of D2-like receptors is dramatically reversed by ketanserin or with atypical compounds displaying significant affinity for the 5-HT2A receptor.

Two main therapeutical advantages of atypical over typical antipsychotics seem to derive from blockade of the 5-HT2A receptor they induce, in addition to that of D2-like (D2 and D3) receptors, that may potentially be related to enhanced HA neuron activity. The first one is a reduced propensity to elicit motor side-effects, exemplified by a reduced cataleptogenic activity in rodents (Meltzer and Nash, 1991; Arnt and Skarsfeldt, 1998). Although a role for the H3 receptor present on striatonigral neurons can be evoked (Garcia et al., 1997), this property of clozapine and atypical antipsychotic drugs cannot be ascribed to enhanced HA neuron activity inasmuch as neither ciproxifan nor a H3-receptor agonist did modify haloperidol-induced catalepsy (Table 3).

The second advantage of atypical antipsychotics is their arousing and pro-cognitive effects resulting in a significant efficacy against negative symptomatology (Kinon and Lieberman, 1996). The positive functional role attributed to HA neurons in processes such as wakefulness, attention, and cognition (Schwartz et al., 1991, 1995) allows to propose that this property of atypical antipsychotics could be related to their unique ability to activate HA neurons. In agreement, activation of these neurons by H3-receptor blockade is accompanied in cats and/or rodents with increase of vigilance, and fast cortical rhythms as well as improved attention and learning ability (Lin et al. 1990;Meguro et al., 1995; Miyazaki et al., 1995). Hence our observation that the positive effect of atypical antipsychotic drugs on HA neuron activity can be further enhanced by a H3-receptor antagonist, suggests the potential use of this class of drugs in schizophrenia.

Acknowledgments

We are grateful to A. Galtier for processing this manuscript. We also thank X. Ligneau for technical advice.

Footnotes

  • Send reprint requests to: Séverine Morisset, Unité de Neurobiologie et Pharmacologie Moléculaire (U.109), Centre Paul Broca de l’INSERM, 2ter rue d’Alésia, 75014 Paris, France.

  • ↵1 This work was supported by grants from the Biomedical and Health Research Program EEC BMH4 CT96 to 0204, the Direction des Recherches Etudes et Techniques (DRET 92/045), and the Wellcome Trust.

  • Abbreviations:
    HA
    histamine
    t-MeHA
    tele-methylhistamine
    (R)α-MeHA
    (R)α-methylhistamine
    HALO
    haloperidol
    CLZ
    clozapine
    OLZ
    olanzapine
    KET
    ketanserin
    CPX
    ciproxifan
    5-HT
    5-hydroxytryptamine
    • Received April 30, 1998.
    • Accepted August 14, 1998.

References

  1. ↵
    1. Alves-Rodrigues A,
    2. Jansen FP,
    3. Leurs R,
    4. Timmerman H,
    5. Prell GD
    (1995) Interaction of clozapine with the histamine H3 receptor in rat brain. Br J Pharmacol 114:1523–1524.
    OpenUrlPubMed
  2. ↵
    1. Arnt J,
    2. Skarsfeldt T
    (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Arrang JM,
    2. Garbarg M,
    3. Lancelot JC,
    4. Lecomte JM,
    5. Pollard H,
    6. Robba M,
    7. Schunack W,
    8. Schwartz JC
    (1987) Highly potent and selective ligands for histamine H3-receptors. Nature (Lond) 327:117–123.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Arrang JM,
    2. Garbarg M,
    3. Schwartz JC
    (1985) Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 15:553–562.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Baldessarini RJ,
    2. Huston-Lyons D,
    3. Campbell A,
    4. Marsh E,
    5. Cohen BM
    (1992) Do central anti-adrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 100:12–16.
    OpenUrl
  6. ↵
    1. Brunello N,
    2. Masotto C,
    3. Steardo L,
    4. Markstein R,
    5. Racagni G
    (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177–213.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Buchanan RW
    (1995) Clozapine—Efficacy and safety (review). Schizophr Bull 21:579–591.
  8. ↵
    1. Busatto GF,
    2. Kerwin RW
    (1997) Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J Psychopharmacol 11:3–12.
  9. ↵
    1. Cheng YC,
    2. Prusoff WH
    (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Clapham J,
    2. Kilpatrick GJ
    (1992) Histamine H3 receptors modulate the release of [3H]acetylcholine from slices of rat entorhinal cortex: Evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 107:919–923.
    OpenUrlPubMed
  11. ↵
    1. Garbarg M,
    2. Arrang JM,
    3. Rouleau A,
    4. Ligneau X,
    5. Dam Trung Tuong M,
    6. Schwartz JC,
    7. Ganellin CR
    (1992) S-[2-(4-Imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J Pharmacol Exp Ther 263:304–310.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Garbarg M,
    2. Dam Trung Tuong M,
    3. Gros C,
    4. Schwartz JC
    (1989a) Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 164:1–11.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Garbarg M,
    2. Pollard H,
    3. Dam Trung Tuong M,
    4. Schwartz JC,
    5. Gros C
    (1989b) Sensitive radioimmunoassays for histamine and tele-methylhistamine in the brain. J Neurochem 53:1724–1730.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Parvez S,
    2. Nagatsu T,
    3. Nagatsu I,
    4. Parvez H
    1. Garbarg M,
    2. Pollard H,
    3. Quach TT,
    4. Schwartz JC
    (1983) Methods in brain histamine research. in Methods in Biogenic Amines Research, eds Parvez S, Nagatsu T, Nagatsu I, Parvez H (Elsevier Science Publishers, Amsterdam), pp 623–662.
  15. ↵
    1. Garcia M,
    2. Floran B,
    3. Arias-Montano JA,
    4. Young JM,
    5. Aceves J
    (1997) Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rats substantia nigra pars reticulata. Neuroscience 80:241–249.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ito C,
    2. Onodera K,
    3. Sakurai E,
    4. Sato M,
    5. Watanabe T
    (1996) Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J Pharmacol Exp Ther 279:271–276.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Itoh Y,
    2. Oishi R,
    3. Nishibori M,
    4. Saeki K
    (1991) Characterisation of histamine release from the rat hypothalamus as measured by in vivo microdialysis. J Neurochem 56:769–774.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kathmann M,
    2. Schlicker E,
    3. Göthert M
    (1994) Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Psychopharmacology 116:464–468.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Kinon BJ,
    2. Lieberman JA
    (1996) Mechanisms of action of atypical antipsychotic drugs—A critical analysis. Psychopharmacology 124:2–34.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Leurs R,
    2. Kathmann M,
    3. Vollinga RC,
    4. Menge WMPB,
    5. Schlicker E,
    6. Timmerman H
    (1996) Histamine homologues discriminating between two functional H3 receptor assays. Evidence for H3 receptor heterogeneity? J Pharmacol Exp Ther 276:1009–1015.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Ligneau X,
    2. Garbarg M,
    3. Vizuete ML,
    4. Diaz J,
    5. Purand K,
    6. Stark H,
    7. Schunack W,
    8. Schwartz JC
    (1994) [125I]Iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. J Pharmacol Exp Ther 271:452–459.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Ligneau X,
    2. Lin JS,
    3. Vanni-Mercier G,
    4. Jouvet M,
    5. Muir JL,
    6. Stark H,
    7. Elz S,
    8. Schunack W,
    9. Schwartz JC
    (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658–666.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Lin JS,
    2. Sakai K,
    3. Vanni-Mercier G,
    4. Arrang JM,
    5. Garbarg M,
    6. Schwartz JC,
    7. Jouvet M
    (1990) Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 523:325–330.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL,
    4. Randall RJ
    (1951) Protein measurements with the Folin phenol reagent. J Biol Chem 193:265–275.
    OpenUrlFREE Full Text
  25. ↵
    1. Meguro KI,
    2. Yanai K,
    3. Sakai N,
    4. Sakurai E,
    5. Maeyama K,
    6. Sasaki H,
    7. Watanabe T
    (1995) Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol Biochem Behav 50:321–325.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Meltzer HY,
    2. Nash JF
    (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604.
    OpenUrlPubMed
  27. ↵
    1. Miyazaki S,
    2. Imaizumi M,
    3. Onodera K
    (1995) Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice. Life Sci 57:2137–2144.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Mochizuki T,
    2. Yamatodani A,
    3. Okakura K,
    4. Takemura M,
    5. Inagaki N,
    6. Wada H
    (1991) In vivo release of neuronal histamine in the hypothalamus of rats measured by microdialysis. Naunyn Schmiedeb Arch Pharmacol 343:190–195.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Nakai T,
    2. Kitamura N,
    3. Hashimoto T,
    4. Kajimoto Y,
    5. Nishino N,
    6. Mita T,
    7. Tanaka C
    (1991) Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30:349–356.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Oishi R,
    2. Itoh Y,
    3. Nishibori M,
    4. Saeki K
    (1989) Effects of the histamine H3-agonist (R)α-methylhistamine and the antagonist thioperamide on histamine metabolism in the mouse and rat brain. J Neurochem 52:1388–1392.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Orange PR,
    2. Heath PR,
    3. Wright SR,
    4. Ramchand CN,
    5. Kolkeiwicz L,
    6. Pearson RCA
    (1996) Individuals with schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor gene. Mol Psychiatry 1:466–469.
    OpenUrlPubMed
  32. ↵
    1. Parker RB,
    2. Waud DR
    (1971) Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. II. Antagonists. J Pharmacol Exp Ther 177:1–24.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Prell GD,
    2. Green JP,
    3. Kaufmann CA,
    4. Khandelwal JK,
    5. Morrishow AM,
    6. Kirch DG,
    7. Linnoila M,
    8. Wyatt RJ
    (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14:93–104.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Rauscher FP,
    2. Nasrallah HA,
    3. Wyatt RJ
    (1980) Cutaneous histamine response in schizophrenia. J Clin Psychiatry 41:44–51.
    OpenUrlPubMed
  35. ↵
    1. Rasmussen K,
    2. Aghajanian GK
    (1988) Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1:101–107.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Schlicker E,
    2. Kathmann M,
    3. Bitschnau H,
    4. Marr I,
    5. Reidemeister S,
    6. Stark H,
    7. Schunack W
    (1996) Potencies of antagonists chemically related to iodoproxyfan at histamine H3 receptors in mouse brain cortex and guinea pig ileum: evidence for H3 receptor heterogeneity? Naunyn Schmiedeb Arch Pharmacol 353:482–488.
    OpenUrlPubMed
  37. ↵
    1. Schlicker E,
    2. Marr I
    (1996) The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedeb Arch Pharmacol 353:290–294.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Schotte A,
    2. Janssen PFM,
    3. Gommeren W,
    4. Luyten WHML,
    5. Van Gompel P,
    6. Lesage AS,
    7. De Loore K,
    8. Leysen JE
    (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57–73.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Schwartz JC,
    2. Pollard H,
    3. Bischoff S,
    4. Rehault MC,
    5. Verdière M
    (1971) Catabolism of 3H-histamine in the rat brain after intracisternal administration. Eur J Pharmacol 16:326–335.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Schwartz JC,
    2. Arrang JM,
    3. Garbarg M,
    4. Pollard H,
    5. Ruat M
    (1991) Histaminergic transmission in the mammalian brain. Physiol Rev 71:1–51.
    OpenUrlFREE Full Text
  41. ↵
    1. Bloom FE,
    2. Kupfer
    1. Schwartz JC,
    2. Arrang JM,
    3. Garbarg M,
    4. Traiffort E
    (1995) Histamine. in Psychopharmacology: The Fourth Generation of Progress, eds Bloom FE, Kupfer (Raven Press, New York), pp 397–405.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleArticle

Atypical Neuroleptics Enhance Histamine Turnover in Brain Via 5-Hydroxytryptamine2A Receptor Blockade

S. Morisset, U. G. Sahm, E. Traiffort, J. Tardivel-Lacombe, J. M. Arrang and J.-C. Schwartz
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 590-596;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section